# EDGAR Filing Document

**Accession Number:** 0002011674
**File Stem:** 0000000000-25-007239
**Filing Date:** 2025-7
**Character Count:** 4452
**Document Hash:** 723656a2f9173e7ec0417f3bf464b1dd
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0000000000-25-007239.hdr.sgml**: 20251121

**ACCESSION NUMBER**: 0000000000-25-007239

**CONFORMED SUBMISSION TYPE**: UPLOAD

**PUBLIC DOCUMENT COUNT**: 2

**FILED AS OF DATE**: 20250709

**FILED FOR**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** YD Bio Ltd
- **CENTRAL INDEX KEY:** 0002011674
- **STANDARD INDUSTRIAL CLASSIFICATION:** SERVICES-MEDICAL LABORATORIES [8071]
- **ORGANIZATION NAME:** 08 Industrial Applications and Services
- **EIN:** 000000000
- **STATE OF INCORPORATION:** E9
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** UPLOAD
- **SEC FILE NUMBER:** 333-283428

**BUSINESS ADDRESS:**
- **STREET 1:** 955 WEST JOHN CARPENTER FREEWAY
- **STREET 2:** SUITE 100-929
- **CITY:** IRVING
- **STATE:** TX
- **ZIP:** 75039
- **BUSINESS PHONE:** 619-500-7747

**MAIL ADDRESS:**
- **STREET 1:** 955 WEST JOHN CARPENTER FREEWAY
- **STREET 2:** SUITE 100-929
- **CITY:** IRVING
- **STATE:** TX
- **ZIP:** 75039

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** True Velocity, Inc./DE
- **DATE OF NAME CHANGE:** 20240209
**PUBLIC REFERENCE ACCESSION NUMBER**: 0001213900-24-101742

## Text-Extract

```

                                                            July 9, 2025

J. Douglas Ramsey, Ph.D
Chief Executive Officer
YD Bio Limited
955 West John Carpenter Freeway
Suite 100-929
Irving, TX 75039

Ethan Shen, Ph.D
Chief Executive Officer
YD Biopharma Limited
12F., No. 3, Xingnan St.
Nangang Dist.
Taipei City 115001, Taiwan

       Re: YD Bio Limited
           Amendment No. 7 to Registration Statement on Form F-4
           Filed July 7, 2025
           File No. 333-283428
Dear J. Douglas Ramsey Ph.D and Ethan Shen Ph.D:

     We have reviewed your amended registration statement and have the
following
comment(s).

        Please respond to this letter by amending your registration statement
and providing
the requested information. If you do not believe a comment applies to your
facts and
circumstances or do not believe an amendment is appropriate, please tell us why
in your
response.

       After reviewing any amendment to your registration statement and the
information
you provide in response to this letter, we may have additional comments. Unless
we note
otherwise, any references to prior comments are to comments in our July 3, 2025
letter.
 July 9, 2025
Page 2
Amendment No. 7 to Registration Statement on Form F-4, Filed July 7, 2025
Exhibits

1.     We note Assumption 2(n) in the legal opinion filed as Exhibit 5.1: "the
issue of any
       Offering Shares pursuant to the Registration Statement and the Merger
Agreement,
       and the issue of the Warrant Shares upon the exercise of the Warrants
pursuant to the
       Merger Agreement and the Warrant Agreement at the time of issuance,
whether as
       principal issue or on the conversion, exchange or exercise of any
Ordinary Shares or
       Warrants, would not result in the Company exceeding its then authorised
share
       capital; and upon the issue of any such Ordinary Shares, the Company
will receive
       consideration for the full issue price thereof which shall be equal to
at least the par
       value thereof." Please remove this assumption as counsel can not assume
that the
       registrant has sufficient authorized shares. Refer to Section II.B.3.a
of Staff Legal
       Bulletin No. 19.
2.     We note that Pubco Warrants are registered pursuant to this registration
statement,
       and the only legal opinion opining on the registered securities, filed
as Exhibit 5.1,
       does not opine on the Pubco Warrants. Please advise whether a separate
legal opinion
       opining on the Pubco Warrants will be filed. Refer to Staff Legal
Bulletin No. 19.
       Please contact Christie Wong at 202-551-3684 or Michael Fay at
202-551-3812 if you
have questions regarding comments on the financial statements and related
matters. Please
contact Margaret Sawicki at 202-551-7153 with any other questions.

                                                            Sincerely,

                                                            Division of
Corporation Finance
                                                            Office of
Industrial Applications and
                                                            Services
cc:   Mathew J. Saur, Esq.
      Marc Rivera, Esq.

```

### Attached PDF Documents

**Attachment 1:** `filename1`

_No text found in this document._